2
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 1
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
10
Urinary Incontinence
2
Sexual Dysfunction, Physiological
2
Melanoma
2
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Secondary Malignant Neoplasm of Bone
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Erectile Dysfunction
1
Desmoid Tumors
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
136
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
68
fludarabine phosphate
62
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Specimen Handling
36
Cisplatin
36
CTLA-4 Antigen
36
Magnetic Resonance Spectroscopy
35
Carboplatin
35
cobimetinib
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Melanoma
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT06472661
2025-11-20
Mel 70
University of Virginia
Phase EARLY_PHASE1
Recruiting
11 enrolled
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled